- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00123760
Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer
A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
Background
Positron Emission Tomography (PET) is a specialised Nuclear Medicine procedure that uses positron emitting radiolabeled tracer molecules to measure biological activity. The commonest of these radiolabeled tracers is 18F-Fluorodeoxyglucose (18F-FDG), which is used to determine abnormal glucose metabolism in tumours and other sites. It has general applications in all areas where abnormal glucose metabolism may be present including circumstances such as differentiating tumour from scar tissue, evaluating the presence of tumour in the light of rising tumour markers and normal morphological imaging techniques and assessing response to therapy where other techniques are deemed to be unhelpful.
The Cross Cancer Institute has recently been funded to establish a PET centre that will establish a research programme to prove the effectiveness of PET scanning in the Canadian health care environment and validate the data that have been developed in other jurisdictions in specific oncologic indications.
Objectives
Primary Objectives - The objectives of the clinical trial are to (a) demonstrate the safety of 18F-FDG synthesised from cyclotron produced radiofluoride in the Coincidence Technologies automated synthesis unit (ASU) in the Edmonton PET Centre facility and (b) confirm the diagnostic effectiveness of 18F-FDG in subjects with known or suspected oncologic disease and to compare this with values published in the literature.
Secondary Objectives - The secondary objectives of the clinical trial are to confirm the general utility and value of 18F-FDG imaging of abnormal glucose metabolism in oncologic applications, particularly with respect to Canadian practice.
Study Design
The proposed clinical trial will be a combined Phase I/II, Phase III, extended Phase III (Phase I/II,III,exIII), diagnostic imaging, controlled, open label, single site, clinical trial in a broad cross-section of CCI patients, including patients with Hodgkin and non-Hodgkin lymphoma, colorectal cancer, breast cancer, melanoma, head and neck cancers, PRUNK, esophageal cancer, thyroid cancer, NSCLC, SCLC, neuroendocrine tumours, and patients with CNS tumours where conventional imaging methods have failed to yield a diagnostic answer.
Each patient will usually receive a single IV injection of 18F-FDG. Imaging will be conducted 30 to 60 minutes after an average injection of 200 - 300 MBq of 18F-FDG in hydrated, fasted patients. Images will be collected for 40 to 60 minutes in 5 - 7 body positions (total counts 5 to 15 million). For the Phase I/II study, images will be interpreted by a single experienced Nuclear Medicine physician with regard to normal physiological uptake of 18F-FDG. For the Phase III study, images will be interpreted independently by two experienced Nuclear Medicine physicians with regard to normal physiological uptake of 18F-FDG. The location and intensity of abnormal 18F-FDG uptake will be noted and correlated with clinical findings, surgical or biopsy results or with conventional imaging techniques, as available. The image review will be supplemented with access to clinical and conventional imaging data in the Phase I/II study. In the Phase III study all images will be reviewed independently by one physician blinded to all clinical data except the primary diagnosis and by one physician with access to all relevant clinical information. In the extended Phase III protocol the images will be interpreted by a single physician with access to relevant clinical information
Statistical Analyses
Sample Size
The Phase I/II stage will enroll 20 subjects without regard for tumour type. The Phase III stage will enroll approximately 300 subjects and the extended Phase III stage will enroll approximately 3000 subjects with the approximate distribution by tumour type as follows:
Tumour Type Phase III:Extended Phase III
- Brain 10:100
- Colorectal 33:330
- Breast 21:210
- Lung (NSCLC & SCLC) 130:1300
- Lymphoma (Hodgkin's and non-Hodgkin's) 22:220
- Head & Neck 16:160
- Neuroendocrine 10:100
- Thyroid 29:290
- Melanoma 15:150
- PRUNK 14:140
Within each cancer subgroup in the Phase III stage, where disease status confirmation is available, the sensitivity (true positive outcomes/true positive outcomes + false negative outcomes) and positive predictive value (true positive outcomes/true positive outcomes + false positive outcomes) will be calculated on a per patient basis. The general criteria for assessment of comparability is that the study group sensitivity percent and positive predictive value percent values have a difference of not less than 15 percent from the appropriately matched literature values. For subgroups with significant patient numbers statistical analysis of comparability will be undertaken.
Criteria for Evaluability of Study Subject Data All subjects enrolled in the Phase I/II stage of the trial will be evaluated for safety. All subjects enrolled in the Phase III and extended Phase III study will be evaluated for safety and efficacy.
Study Population
Number of Subjects to be Studied Phase I/II stage: ~ 20 Phase III stage: ~ 300 Extended Phase III stage: ~ 3000 Some variation in the patient numbers studied is anticipated in the Phase III and extended Phase III depending on local conditions and timing.
Inclusion Criteria for Selection of Study Subjects
Patients will be included in the study if they meet all of the following general criteria.
- Male or female.
- Known or suspected primary or metastatic tumours.
- Age greater than or equal to 15
- If female of child-bearing potential, a reliable method of contraception must be combined with a negative pregnancy test before entering the study (contraception must be used for 1 month after the last administration of 18F-FDG). If male, a barrier method of contraception should be used for up to 1 month after the last administration of 18F-FDG.
- Able and willing to follow instructions and comply with the protocol.
- Provide written informed consent prior to participation in the study.
- Karnofsky Performance Scale Score 60-100.
Exclusion Criteria
Patients will be excluded from the study if they meet any of the following criteria:
- significant renal impairment (serum creatinine > 200 µmol/L).
- Coagulopathy (prothrombin time [PT] or activated partial thromboplastin time [APTT] >1.5 times control).
- Significant Thrombocytopenia (platelet count < 75,000/mm3).
- Granulocytopenia (absolute neutrophil count < 1,000/mm3).
- Blood glucose level Significant liver function impairment (total bilirubin > 2.0 mg/dL; AST or ALT > 3 times the upper limit of normal) or greater than 10.
- Presence of a severe infection.
- Having had surgery or radiotherapy within 10 days of the planned imaging study.
- Nursing or pregnant females.
- Age less than 15.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female. (If female of child-bearing potential and outside of the window of 10 days since the last menstrual period, a negative serum or urine pregnancy test is required.)
- Known or suspected primary or metastatic tumours
- Age equal to or greater than 15 years
- Able and willing to follow instructions and comply with the protocol
- Provide written informed consent prior to participation in this study
- Karnofsky Performance Scale score 60-100
Exclusion Criteria:
- Nursing or pregnant females
- Presence of a severe infection
- Age less than 15 years
- Having had surgery or radiotherapy within 10 days of the planned imaging study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To demonstrate the safety of 18F-FDG synthesized from cyclotron produced radiofluoride in the Coincidence Technologies automated synthesis unit (ASU) in the Edmonton PET Centre facility
Time Frame: One Year
|
One Year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To confirm the diagnostic effectiveness of 18F-FDG in subjects with known or suspected oncologic disease and compare this to literature values
Time Frame: One Year
|
One Year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alexander McEwan, MB, MSc, MD, FRCP, AHS Cancer Control Alberta
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Neoplasms by Site
- Endocrine System Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Endocrine Gland Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Thyroid Diseases
- Head and Neck Neoplasms
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neoplasms
- Lung Neoplasms
- Colorectal Neoplasms
- Brain Neoplasms
- Thyroid Neoplasms
Other Study ID Numbers
- SP-11-0035/DX-FDG-001/21221
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
Clinical Trials on Positron Emission Tomography (PET) scan
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnOropharyngeal Squamous Cell Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma
-
University of Texas Southwestern Medical CenterWithdrawn
-
M.D. Anderson Cancer CenterGE HealthcareCompletedLung CancerUnited States
-
Centre Henri BecquerelCompleted
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdult Solid NeoplasmUnited States
-
University of CincinnatiActive, not recruitingLiver Metastases | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver CancerUnited States
-
Université de SherbrookeCanadian Cancer Society (CCS); Fonds de la Recherche en Santé du Québec; Merck... and other collaboratorsCompletedMetastatic Castration-resistant Prostate CancerCanada
-
Jagiellonian UniversityMedical University of WarsawCompletedNeurodegenerative Diseases | Brain Neoplasms | Neuroendocrine TumorsPoland
-
Stanford UniversityNational Cancer Institute (NCI)CompletedPancreatic Carcinoma | Healthy SubjectUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedCigarette Smoking-Related CarcinomaUnited States